Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: J Thorac Oncol. 2020 Oct 22;16(2):269–277. doi: 10.1016/j.jtho.2020.10.013

Figure 1. CONSORT diagram.

Figure 1.

This study was a comparison of 86 patients with locally advanced non-small cell lung cancer (LA-NSCLC) treated with passive scattering proton therapy (PSPT) as part of a randomized clinical trial (clinicaltrials.gov NCT00915005). The intensity-modulated proton therapy (IMPT) group included 51 patients with LA-NSCLC who received IMPT at MD Anderson while enrolled in the prospective patient registry Normal Tissue Toxicity for Proton Therapy (clinicaltrial.gov NCT00991094), plus 2 patients from the NCT00915005 who ultimately received IMPT treatment.